EMZOR Pharmaceutical Industries Ltd
Plot 3C, Block A, Aswani Market Road, Isolo.
P. O. Box 1575 Oshodi, Lagos, Nigeria.
Tel: +234-708 060 6000
email: customerservice@emzorpharma.com
website: www.emzorpharma.com

RC. 61894

FMDQ SECURITIES EXCHANGE LIMITED COMMERCIAL PAPERS QUOTATION COMPLIANCE REPORT

Name of Issuer	EMZOR PHARMACEUTICAL INDUSTRIES LIMITED
Issue/Programme Description	ISSUE OF NGN10,000,000,000.00 SERIES 2 COMMERCIAL PAPER NOTE UNDER ITS NGN 10,000,000,000 COMMERCIAL PAPER ISSUANCE PROGRAMME
Name of IPCA[1]/IPA[2]	RENAISSANCE SECURITIES (NIGERIA) LIMITED
Reporting Period	Q2-2026

S/N	NOTIFICATION	YES	NO	N/A[3]
1.	Have there been any published accounts of the Company and/or consolidated accounts of the Group (where applicable) after the date of last submission?	X		
2.	Have there been any publicly available interim reports (provisional or unaudited) of the Company after the date of last submission?		X	
3.	Were there any changes to the Board of Directors of the Issuer?	X		
4.	Have there been any changes in capital structure or any other corporate action that could affect the price of the Commercial Paper (CP) in the market?		X	
5.	Have there been any alterations to the Memorandum and Articles of Association or Constitution of the Company?		X	
6.	Have there been any changes in the general character or nature of the business of the Company or of the Company's Group?		X	
7.	Are there any circumstances that may affect the Company's creditworthiness?		X	
8.	Have there been any changes in the terms of the Issue as contained in the Offer Documents?		X	
9.	Have there been any proposed changes to the parties to the Issue including, but not limited to, the IPCA or IPA and CPA[4], solicitor, fixed income specialist, and such other parties as are stated in the Offer Documents?		X	
10.	Have there been any leakages of the financial statement and ratings or any other information that will affect the price of the CP?		X	
11.	Have there been any resolutions passed at an Annual General Meeting, Extraordinary General Meeting, or any other meeting that is likely to affect the terms of the Issue?		X	
12.	Have there been any circulars, notices, reports, documents, or announcements issued to holders of the CP or made in respect of the CP?		X	
13.	Have there been any decisions of any subsidiaries of the Company to acquire another business or section of another business?		X	

[1] IPCA – Issuing, Placing, Paying and Collecting Agent
[2] IPA – Issuing and Placing Agent
[3] N/A – Not Applicable
[4] CPA – Collecting and Paying Agent

IF THE ANSWER TO ANY OF THE QUESTIONS ABOVE IS "YES", THE ISSUER IS REQUIRED TO PROVIDE ADDITIONAL INFORMATION/DETAILS IN A SEPARATE SHEET OR ATTACH SUPPORTING DOCUMENTATION.

THIS COMPLIANCE REPORT WAS PREPARED BY:

Name of Sponsor: RENAISSANCE SECURITIES (NIGERIA) LIMITED

Name of Authorised Representative: CHINONSO EZE

Designation: FINANCIAL CONTROLLER

Signature: _____ Date: 6th July 2026

FOR AND ON BEHALF OF:

EMZOR PHARMACEUTICAL INDUSTRIES LIMITED

[NAME OF ISSUER]